HOTH Company Profile and Key Details

HOTH has shown mixed momentum, gaining 0.94% over the past week and -23.57% over the past quarter, though year-to-date performance is up 8.08%. Short-term trend indicators are bullishly aligned (SMA20 10.25%, SMA50 3.23%, SMA200 -15.6%). The stock’s 14-day RSI is 55.26 (neutral), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -50.83% below its high and over 58.68% above its low. Average 10-day trading volume of 18.94 million shares is significantly above the 3-month average of 11.87 million, indicating heightened recent market interest.

Hoth Therapeutics, Inc. has 13.26 million shares outstanding. The public float is 12.71 million shares, elevated short interest at 1.94% of float. This equals 255.81 thousand shares. The short ratio is 0.83 days. Institutional investors hold 4.24% of the float. Insiders own 2.89%.

Hoth Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.45. This means the shares are trading above this model’s fair value.

Hoth Therapeutics, Inc. generated EPS of -$1.06 over the past year. Five-year average earnings growth is 42.82%. Wall Street analysts project EPS growth of 18.08% annually over the next five years. The latest quarter delivered EPS of -$0.17. The next quarter is forecast at -$0.10. Next year's EPS is expected at $38.30. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $5.00. The high target offers 449.45% upside. The low target suggests 449.45% downside. The mean target is $5.00. This offers 449.45% upside. Hoth Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 15, 2026, missed forecasts by 23.37%. The prior quarter beat by 55.19%. Over the last six quarters, Apple has recorded several small beats. These include -17.95% in March 28, 2025.

Hoth Therapeutics, Inc. (NASDAQ:HOTH) closed at $0.91 USD, gaining $0.10 (12.95%) from the previous close of $0.80. The stock is currently mid-range between its 52-week high and low $0.49 and $2.45. With a market capitalization of about $12.02 million, Hoth Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.53). Key stats such as the average daily volume over the past year has been around 10.56 million shares, trading with heavier-than-usual volume. Headquartered in New York, NY, Hoth Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robb Knie, the company employs approximately 6 people and listed since February 15, 2019. Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders.

Hoth Therapeutics, Inc. (NASDAQ:HOTH) shares are flat 8.08% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Hoth Therapeutics, Inc. trading at a premium to the broader market with a P/E of -1.08. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.95, suggesting 663.74% upside. Our AI forecast model points to short-term strength (7.69% over two weeks), a medium-term rise (8.79% over three months), and a longer-term gain (201.1% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Hoth Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.69%, with price expected at $0.98 by July 22, 2026, within a range of $0.70 to $1.28 3-Month Outlook: Projected rise of 8.79%, reaching $0.99 by October 06, 2026, with a range of $0.92 to $1.06. 1-Year Outlook: Projected gain of 201.1%, with price at $2.74 by July 08, 2027, within a range of $0.00 to $2.50.

Hoth Therapeutics, Inc. trades at a P/E ratio of -1.08, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.31 trading at moderately above to book value. The P/FCF stands at -1.15, also above market averages.